Octohydroaminoacridine succinate

Drug Profile

Octohydroaminoacridine succinate

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Changchun Huayang High-tech
  • Class Aminoacridines
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 16 Aug 2017 Phase-III clinical trials in Alzheimer's disease in China (PO) (NCT03283059)
  • 01 Jun 2011 Phase-II clinical trials in Alzheimer's disease in China (PO) (NCT01569516)
  • 31 Dec 2010 Phase-I clinical trials in Alzheimer's disease in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top